The Indian Council for Medical Research (ICMR) has said that the Indian vaccine against Covid-19, Covaxin, has attracted global attention.
In a tweet, the ICMR said: “India’s indigenous vaccine against covaxin # Covid19, a product of the ICMR-Bharat Biotech collaboration, achieves a remarkable feat. The data generated from India underscores an impressive safety and immunogenicity profile of Covaxin and sparks the interest of the Lancet to publish it. “
The ICMR said: “The encouraging results from the COVAXIN phase I and phase II trials have paved the way for the phase III clinical trial in India, which is currently underway at 22 sites.”
The New Delhi-based Institute of Medical Sciences (AIIMS) invited volunteers for the phase III clinical trial of the indigenously developed Covid-19 vaccine candidate ‘Covaxin’ for which it is one of the sites.
“AIIMS, New Delhi is a site for the phase III clinical trial of COVAXIN. This is an inactivated full virion vaccine co-sponsored by the Indian Council for Medical Research (ICMR) and Bharat Biotech, ”AIIMS said in an announcement.
AIIMS Center for Community Medicine, Dr. Sanjay K Rai reported through the announcement that Phase I / II trials (safety and immunogenicity) have already been completed.
.
